Novel selective hypotensive vasopressin peptides: cardiovascular and structure-activity-relationship studies

被引:9
作者
Chan, WY
Levi, R
Wo, NC
Koyama, M
Stoev, S
Cheng, LL
Manning, M
机构
[1] Cornell Univ, Weill Med Coll, Dept Pharmacol, New York, NY 10021 USA
[2] Med Coll Ohio, Dept Biochem & Mol Biol, Toledo, OH 43699 USA
关键词
vasopressin peptide; selective hypotensive; vasopressin receptor; vasodilating; vasopressin receptor subtype; new; structure-activity-relationship;
D O I
10.1016/S0014-2999(01)00959-1
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Recently, we discovered a series of peripheral acting selective hypotensive vasopressin peptides. Whether these peptides may interact with receptors outside the vasopressin receptor family and affect cardiac function could not be excluded. Accordingly, we tested the effects of these hypotensive vasopressin peptides on blood pressure and heart rate in intact rats and on the heart rate, ventricular contractile force and coronary flow of isolated perfused rat hearts. We found that the hypotensive vasopressin peptides did not modify cardiac function, either in vivo or in vitro. The vasodepressor potency was reduced when assayed in rats with vasopressin-maintained baseline blood pressure, suggesting that vasopressin and the hypotensive peptide compete for a common vasodilating vasopressin receptor in the vasculature. We have now synthesized more potent and radioiodinatable hypotensive peptides that could serve as lead compounds for the development of a radiomarker for the putative vasodilating vasopressin receptor. (C) 2001 Published by Elsevier Science B.V.
引用
收藏
页码:65 / 72
页数:8
相关论文
共 24 条
[1]   HEMODYNAMIC AND COAGULATION RESPONSES TO 1-DESAMINO[8-D-ARGININE] VASOPRESSIN IN PATIENTS WITH CONGENITAL NEPHROGENIC DIABETES-INSIPIDUS [J].
BICHET, DG ;
RAZI, M ;
LONERGAN, M ;
ARTHUS, MF ;
PAPUKNA, V ;
KORTAS, C ;
BARJON, JN .
NEW ENGLAND JOURNAL OF MEDICINE, 1988, 318 (14) :881-887
[2]  
Chan WY, 1998, ADV EXP MED BIOL, V449, P451
[3]   Discovery of novel selective hypotensive vasopressin peptides that exhibit little or no functional interactions with known oxytocin/vasopressin receptors [J].
Chan, WY ;
Wo, NC ;
Stoev, S ;
Cheng, LL ;
Manning, M .
BRITISH JOURNAL OF PHARMACOLOGY, 1998, 125 (04) :803-811
[4]  
DYKES DF, 1974, J MED CHEM, V17, P250
[5]   A MODIFICATION OF THE METHOD OF DALE AND LAIDLAW FOR STANDARDIZATION OF POSTERIOR PITUITARY EXTRACT [J].
HOLTON, P .
BRITISH JOURNAL OF PHARMACOLOGY AND CHEMOTHERAPY, 1948, 3 (04) :328-334
[6]   L-NAME ANTAGONIZES VASOPRESSIN V-2-INDUCED VASODILATATION IN DOGS [J].
LIARD, JF .
AMERICAN JOURNAL OF PHYSIOLOGY, 1994, 266 (01) :H99-+
[7]   SOLID-PHASE SYNTHESIS OF 16 POTENT (SELECTIVE AND NONSELECTIVE) INVIVO ANTAGONISTS OF OXYTOCIN [J].
MANNING, M ;
KRUSZYNSKI, M ;
BANKOWSKI, K ;
OLMA, A ;
LAMMEK, B ;
CHENG, LL ;
KLIS, WA ;
SETO, J ;
HALDAR, J ;
SAWYER, WH .
JOURNAL OF MEDICINAL CHEMISTRY, 1989, 32 (02) :382-391
[8]  
Manning M, 1999, J PEPT SCI, V5, P472
[9]   DESIGN OF MORE POTENT ANTAGONISTS OF THE ANTI-DIURETIC RESPONSES TO ARGININE-VASOPRESSIN [J].
MANNING, M ;
OLMA, A ;
KLIS, WA ;
KOLODZIEJCZYK, AM ;
SETO, J ;
SAWYER, WH .
JOURNAL OF MEDICINAL CHEMISTRY, 1982, 25 (01) :45-50
[10]   Discovery and design of novel vasopressin hypotensive peptide agonists [J].
Manning, M ;
Stoev, S ;
Cheng, LL ;
Wo, NC ;
Chan, WY .
JOURNAL OF RECEPTOR AND SIGNAL TRANSDUCTION RESEARCH, 1999, 19 (1-4) :631-644